SEC Filings
Charles River Agrees To Pay Approximately $470 Million To Expand Into Clinical Testing
Frontage operations would broaden its human-trial testing business, with up to $75 million more payable based on performance.
SEC Filings
Frontage operations would broaden its human-trial testing business, with up to $75 million more payable based on performance.
SEC Filings
The company expects to submit the report within five calendar days while management finishes assembling and checking information.
SEC Filings
The planned purchase adds peptide drug discovery to argenx’s antibody business, with potential oral and long-acting treatments.
SEC Filings
Clal holds 85,519 shares for its own account; subsidiaries independently manage the shares held for public clients.
SEC Filings
The drug developer’s most advanced candidate is in late-stage testing for relapsing multiple sclerosis.
SEC Filings
The company denies wrongdoing as holders prepare to vote on its proposed acquisition by onsemi on November 17.
SEC Filings
The board backs the proposal unanimously, while broker-held shareholders face a warning about relying on earlier voting instructions.
SEC Filings
The ownership update changes entity names and retains agreements to support Tungsten OpCo Holder’s board nominees.
SEC Filings
The funds cited investment purposes and left further purchases or sales open, while Robert Nelsen reported 7.3% beneficial ownership.
SEC Filings
Baker-managed funds also hold prefunded warrants and nonvoting preferred stock, with limits on conversion into common shares.
SEC Filings
Family-trust transfers of Hercules partnership units left the participants’ total beneficial share ownership unchanged.
SEC Filings
The shares were held by Irenic's Evergreen Master Fund, which intends to move them to its wholly owned ICM ARI Investor entity.